This review is justified by the need to bridge the gap between existing preclinical and clinical data, focusing on the mechanisms of JAK2 involvement in pediatric leukemia and evaluating the potential of JAK2 inhibitors as targeted therapies for children. Here, JAK2 is linked to leukemia.